Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | PER2 | O15055 | 1/20 | 0.32 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.32 |
| ▸ | TLR4 | O00206 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18883354 | 1.00 | DPP4 (0.39) | DPP4MAPTPIK3CDPER2CRY2 | |
| SCHEMBL18821184 | 1.00 | DPP4 (0.39) | DPP4MAPTPIK3CDPER2CRY2 | |
| SCHEMBL18821191 | 0.87 | ACE (0.36) | DPP4MAPTPIK3CDPER2CRY2 | |
| SCHEMBL12545572 | 0.87 | ACE (0.36) | DPP4MAPTPIK3CDPER2CRY2 | |
| SCHEMBL18883357 | 0.87 | ACE (0.36) | DPP4MAPTPIK3CDPER2CRY2 | |
| SCHEMBL23791957 | 0.84 | MAPT (0.39) | DPP4MAPTPIK3CDL3MBTL1 | |
| SCHEMBL16472302 | 0.80 | DPP4 (0.42) | DPP4MAPTPIK3CDL3MBTL1 | |
| SCHEMBL16472346 | 0.80 | DPP4 (0.42) | DPP4MAPTPIK3CDL3MBTL1 | |
| SCHEMBL16472394 | 0.80 | DPP4 (0.42) | DPP4MAPTPIK3CDL3MBTL1 | |
| SCHEMBL16472435 | 0.77 | PIK3CD (0.52) | DPP4MAPTPIK3CDPER2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4289845-A1 | TRIHETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Shanghai Apeiron Therapeutics Company Limited (CN) | 2023-12-13 | — | — | EP | disclosed |
| US-11787812-B2 | Substituted pyrazolo[4,3-d]pyrimidines and imidazo[5,1 -f][1,2,4]triazines as androgen receptor and phosphodiesterase dual inhibitors | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-10-17 | — | — | US | disclosed |
| US-20230135152-A1 | PIKFYVE KINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-04 | — | — | US | disclosed |
| US-20230135152-A1 | PIKFYVE KINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-04 | — | — | US | disclosed |
| US-20200347043-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2020-11-05 | — | — | US | disclosed |
| US-20190330224-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. | 2019-10-31 | — | — | US | disclosed |
| US-10179793-B2 | ACC inhibitors and uses thereof | GILEAD APOLLO, LLC (US) | 2019-01-15 | — | — | US | disclosed |
| US-9969724-B2 | Factor IXa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-05-15 | — | — | US | disclosed |
| US-20170253601-A1 | Substituted Pyrrolidine Compounds | Epizyme, Inc. (US) | 2017-09-07 | — | — | US | disclosed |
| US-20170253601-A1 | Substituted Pyrrolidine Compounds | Epizyme, Inc. (US) | 2017-09-07 | — | — | US | disclosed |
| US-20110098276-A1 | OXYCARBAMOYL COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2011-04-28 | — | — | US | disclosed |
| US-20110082117-A1 | PHENYL SULFONAMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-07 | — | — | US | disclosed |
| US-7799822-B2 | Phenyl sulfonamides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-21 | — | — | US | disclosed |
| US-20090105271-A1 | PYRIDYL SULFONAMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-04-23 | — | — | US | disclosed |
| US-20080027067-A1 | Heterocyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-31 | — | — | US | disclosed |
| US-20070054909-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-7179819-B2 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-20 | — | — | US | disclosed |
| US-20070014725-A1 | Conjugates of macrocyclic metal complexes with biomolecules and their use for the production of agents for NMR diagnosis and radiodiagnosis as well as radiotherapy | SCHERING AG (DE) | 2007-01-18 | — | — | US | disclosed |
| US-7164016-B2 | Macrocyclic metal complexes and their use for the production of conjugates with biomolecules | SCHERING AG (DE) | 2007-01-16 | — | — | US | disclosed |
| US-20070009442-A1 | Macrocyclic metal complexes and their use for the production of conjugates with biomolecules | SCHERING AG (DE) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135152-A1 | PIKFYVE KINASE INHIBITORS | PIKFYVE, PIP5K1B, PIP5K1C | DPP4 2363/4885MAPT 1501/4885PIK3CD 12/4885 |
| US-20110098276-A1 | OXYCARBAMOYL COMPOUNDS AND THE USE THEREOF | CACNA1B, ORAI1, CACNA1I | DPP4 4493/4885MAPT 1884/4885PIK3CD 2783/4885 |
| US-20070014725-A1 | Conjugates of macrocyclic metal complexes with biomolecules and their use for the production of agents for NMR diagnosis and radiodiagnosis as well as radiotherapy | CA13, CA14, CA12 | DPP4 2074/4885MAPT 1536/4885PIK3CD 4815/4885 |
| US-20070054909-A1 | VLA-4 inhibitor compounds | VCAM1, ITGB4, ICAM1 | DPP4 288/4885MAPT 3296/4885PIK3CD 1966/4885 |
| US-20080027067-A1 | Heterocyclic derivatives as modulators of ion channels | TRPV1, KCNJ2, KCNN3 | DPP4 2235/4885MAPT 1856/4885PIK3CD 484/4885 |
| US-10179793-B2 | ACC inhibitors and uses thereof | ACACA, ACACB, ACAT2 | DPP4 1148/4885MAPT 2490/4885PIK3CD 1107/4885 |
| US-20090105271-A1 | PYRIDYL SULFONAMIDES AS MODULATORS OF ION CHANNELS | KCNJ2, TRPV1, KCNJ1 | DPP4 1997/4885MAPT 2371/4885PIK3CD 442/4885 |
| US-20110082117-A1 | PHENYL SULFONAMIDES AS MODULATORS OF ION CHANNELS | TRPV1, KCNJ2, TRPA1 | DPP4 1465/4885MAPT 2194/4885PIK3CD 633/4885 |
| US-11787812-B2 | Substituted pyrazolo[4,3-d]pyrimidines and imidazo[5,1 -f][1,2,4]triazines as androgen receptor and phosphodiesterase dual inhibitors | PDE5A, AR, PDE3A | DPP4 460/4885MAPT 4610/4885PIK3CD 282/4885 |
| US-20200347043-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | DPP4 3388/4885MAPT 3370/4885PIK3CD 687/4885 |
| US-20170253601-A1 | Substituted Pyrrolidine Compounds | SMYD2, SMYD3, SNRPD2 | DPP4 4456/4885MAPT 3571/4885PIK3CD 4734/4885 |
| US-20070009442-A1 | Macrocyclic metal complexes and their use for the production of conjugates with biomolecules | CA13, MPI, CA14 | DPP4 1528/4885MAPT 1267/4885PIK3CD 4785/4885 |
| US-20190330224-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | DPP4 1148/4885MAPT 2490/4885PIK3CD 1107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.